Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
Top Cited Papers
- 1 April 2005
- journal article
- research article
- Published by Elsevier in Cancer Cell
- Vol. 7 (4), 387-397
- https://doi.org/10.1016/j.ccr.2005.03.023
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- The International HapMap ProjectNature, 2003
- Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the diseaseBlood, 2003
- SWISS-MODEL: an automated protein homology-modeling serverNucleic Acids Research, 2003
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporine 1 1Edited by I. A. WilsonJournal of Molecular Biology, 1999
- A 12-Item Short-Form Health SurveyMedical Care, 1996
- Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.Journal of Clinical Investigation, 1993
- SETOR: Hardware-lighted three-dimensional solid model representations of macromoleculesJournal of Molecular Graphics, 1993